Logo

Atugen Raises 5M for Developing siRNA Therapeutics

Mar 15, 2004

NEW YORK, March 15 (GenomeWeb News) - RNAi firm Atugen has raised €5 million in a third financing round, the company said today.

 

The financing round was managed by WestLBPanmure and co-led by new investor Novartis Venture Fund and funds advised by Apax Partners. Previous investor MPM Capital also joined the round.

 

Atugen, based in Berlin, Germany, is developing siRNA therapeutics.

Breaking News
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.